



Dated: 2nd May, 2018

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138"

Ref.: "ASTEC"

Sub: Outcome of the Board Meeting

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Wednesday, 2nd May, 2018 (which commenced at 5.00 p.m. and concluded at 7.25 p.m.), *inter alia*, has approved / noted the following:-

(a) The Compensation Committee, at its Meeting held today, i.e., on 2nd May, 2018, has approved / considered the following:-

(i) Allotment of 13,500 (Thirteen Thousand Five Hundred) Equity Shares of Face Value Rs.10/- (Rupees Ten Only) each to the employees of the Company upon exercise of 13,500 (Thirteen Thousand Five Hundred) Options granted to them, at an Exercise Price of Rs.34/- (Rupees Thirty Four Only) per Equity Share. The amount realized by the Company upon exercise of the said Options is Rs.4,59,000/- (Rupees Four Lakh Fifty Nine Thousand Only) [13,500 Options @ Rs.34/- per Option], under Astec Employee Stock Options Plan, 2012 (ESOP 2012), as fully paid-up.

The above 13,500 (Thirteen Thousand Five Hundred) Equity Shares shall rank *pari passu* with the existing Equity Shares of the Company in all respects, including dividend entitlement.

(ii) Allotment of 4,000 (Four Thousand) Equity Shares of Face Value Rs.10/- (Rupees Ten Only) each to the employees of the Company upon exercise of 4,000 (Four Thousand) Options granted to them, at an Exercise Price of Rs.387.35/- (Rupees Three Hundred Eighty Seven and Thirty Five Paise Only) per Equity Share. The amount realized by the Company upon exercise of the said Options is Rs.15,49,400/- (Rupees Fifteen Lakh Forty Nine Thousand Four Hundred Only) [4,000 Options @ Rs.387.35/- per Option], under Employees Stock Options Scheme, 2015 (ESOS 2015), as fully paid-up.

The above 4,000 (Four Thousand) Equity Shares shall rank *pari passu* with the existing Equity Shares of the Company in all respects, including dividend entitlement.



With the above allotment as mentioned in point no. (i) and (ii), the total Paid-Up Equity Share Capital of the Company stands at Rs.19,54,51,550/- (Rupees Nineteen Crore Fifty Four Lakh Fifty One Thousand Five Hundred Fifty Only) [divided into 1,95,45,155 (One Crore Ninety Five Lakh Forty Five Thousand One Hundred Fifty Five) Equity Shares of Rs.10/- (Rupees Ten Only) each].

- (b) Upon recommendation of the Audit Committee, the Board of Directors has approved the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Financial Year ended 31st March, 2018 and the Statement of Assets and Liabilities as on 31st March, 2018 (enclosed herewith).
- (c) Took note of the Statutory Auditors' Report on the Audited Financial Results (Standalone & Consolidated) for the Quarter and Financial Year ended 31st March, 2018 (enclosed herewith).

The Report of Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended 31st March, 2018.

- (d) Recommended ratification of appointment of M/s. BSR & Co. LLP, Chartered Accountants (Firm Registration Number: 101248W/W-100022), Statutory Auditors of the Company for the period commencing from conclusion of the 24th (Twenty Fourth) Annual General Meeting upto conclusion of 25th (Twenty Fifth) Annual General Meeting, subject to approval of the Shareholders.
- (e) Recommended Final Dividend of 15% (Fifteen per cent) on the Equity Share Capital of the Company, i.e., Rs.1.50 (Rupee One and Paise Fifty Only) per Equity Share of Face Value of Rs.10/- (Rupees Ten Only) each for the Financial Year ended 31st March, 2018, subject to approval of the Shareholders at the ensuing 24th (Twenty Fourth) Annual General Meeting of the Company.
- (f) Considered and fixed the date of the 24th (Twenty Fourth) Annual General Meeting and related matters as under:-
- (i) The 24th (Twenty Fourth) Annual General Meeting of the Shareholders of the Company will be held on Wednesday, 1st August, 2018 at 3.30 p.m. at the "Auditorium", Godrej One, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai – 400079, Maharashtra.
- (ii) The Book Closure Dates for the purposes of the 24th (Twenty Fourth) Annual General Meeting and payment of Final Dividend are from Monday, 23rd July, 2018 to Wednesday, 25th July, 2018. The dividend will be paid on Friday, 10th August, 2018.
- (iii) The Register of Members and Share Transfer Books will remain closed from Monday, 23rd July, 2018 to Wednesday, 25th July, 2018.



- (g) Pursuant to Regulation 8 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Board of Directors has amended the “Code of Conduct for Prevention of Insider Trading” of the Company (“said Code”) to align the same with Godrej group. The amended copy of the said Code is uploaded on the website of the Company, viz. www.astecsl.com.
- (h) Approved the increase in limit of raising funds by issuance of Commercial Papers (CPs) by Rs.50 Crore (Rupees Fifty Crore Only) [i.e. enhancement of existing limit of Rs.50 Crore (Rupees Fifty Crore Only) to Rs.100 Crore (Rupees One Hundred Crore Only)].

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

Tejal Jariwala
Company Secretary & Compliance Officer
(ACS 32441)





Astec Life Sciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli(East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Standalone Financial Results for the Quarter and Financial Year ended 31st March, 2018



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	STANDALONE				
		3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue From Operations (Refer note 9)	12,836.09	7,428.50	9,045.73	37,084.52	31,275.74
II	Other Income	177.93	168.82	83.40	810.62	284.54
III	Total Income (I+II)	13,014.02	7,597.32	9,129.13	37,895.14	31,560.28
IV	Expenses					
	Cost of materials consumed	6,803.98	4,452.40	6,037.64	22,421.97	17,912.07
	Purchase of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,365.04	(111.17)	(430.18)	1,082.92	27.64
	Excise duty	-	-	436.74	326.10	1,472.89
	Employee benefits expense	548.19	558.62	642.16	2,170.82	2,037.57
	Finance costs	231.02	257.46	270.12	1,065.90	1,222.98
	Depreciation and amortisation expense	399.70	366.59	441.83	1,467.27	1,367.31
	Other expenses	1,005.15	1,184.35	712.59	4,207.59	3,596.89
	Total expenses (IV)	10,353.08	6,708.25	8,110.90	32,742.57	27,637.35
V	Profit / (loss) before exceptional items and tax (III - IV)	2,660.94	889.07	1,018.23	5,152.57	3,922.93
VI	Exceptional Items (Refer note 8)	-	415.21	(603.18)	415.21	(1,060.21)
VII	Profit / (loss) before tax (V+VI)	2,660.94	1,304.28	415.05	5,567.78	2,862.72
VIII	Tax Expense:					
	(1) Current tax	968.57	424.15	86.94	1,737.13	609.27
	(2) Deferred tax	(17.42)	35.31	(21.11)	206.99	344.03
	(3) Tax for earlier years	-	126.58	-	126.58	-
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	1,709.79	718.24	349.22	3,497.08	1,909.42
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	1,709.79	718.24	349.22	3,497.08	1,909.42
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	16.62	(10.21)	(3.39)	(14.00)	(10.32)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(5.75)	3.53	1.18	4.85	3.58
	B (i) Items that will be reclassified to profit or loss	68.92	62.14	(5.96)	(29.29)	(5.96)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(23.85)	(21.50)	2.06	10.14	2.06
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	1,765.73	752.20	343.11	3,468.78	1,898.78
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,952.77	1,952.77	1,951.29	1,952.77	1,951.29
XVII	Other Equity excluding Revaluation Reserve	-	-	-	15,015.92	11,847.26
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic	8.76	3.68	1.79	17.91	9.79
	(2) Diluted	8.74	3.67	1.79	17.88	9.77

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 2nd May, 2018.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2018 and 31st March, 2017 are the balancing figures between audited figures in respect of the full Financial Year and the published Year To Date figures upto the third Quarter of the Financial Year.
- The report of the Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results of the Company for the Quarter and Financial Year ended 31st March, 2018.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2018, subject to approval of the Shareholders at the ensuing 24th Annual General Meeting of the Company.
- Figures of corresponding previous year / period have been re-grouped/re-classified wherever necessary, to conform to this period's classification.
- Exceptional Items (as disclosed in the columns "3 months ended 31st December, 2017" and "Year ended 31st March, 2018" comprises (a) gain on mutually cancelled agreement for supply of product with one of its multi-national customer aggregating Rs. 1,932.83 Lakh; (b) inventory written off aggregating Rs. 727.83 Lakh; and (c) property, plant & equipment written off aggregating Rs. 789.79 Lakh. Exceptional Items (as disclosed in the columns "3 months ended 31st March 2017" and "Year ended 31st March, 2017" comprises property, plant & equipment written off aggregating to Rs. 603.18 Lakh and Rs. 1,060.21 Lakh respectively.
- According to the requirements of Ind-AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous Quarter ended 31st March, 2017 and for the Financial Year ended 31st March, 2017 were and are reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ('GST') from 1st July, 2017 replacing Excise duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the Quarters ended 31st March, 2018 and 31st December, 2017 is reported net of GST. Had the previously reported revenues were shown net of excise duty, comparative revenue of the Company would have been as follows:

(Rs. in Lakh)

Particulars	3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
Net revenue from operations	12,836.09	7,428.50	8,608.99	36,758.42	29,802.85

For Astec Life Sciences Limited

Ashok Hiremath
Managing Director
DIN :- 00349345
Wednesday, 2nd May, 2018, Mumbai



B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditors' Report on quarterly standalone financial results and year to date standalone results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To Board of Directors of Astec LifeSciences Limited

We have audited the accompanying standalone financial results of Astec LifeSciences Limited ('the Company') for the quarter ended 31 March 2018 and the year to date results for the period from 1 April 2017 to 31 March 2018 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the current and previous financial year respectively. Also, the figures up to the end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 2 May 2018.

These quarterly standalone financial results as well as the year to date standalone financial results have been prepared on the basis of the reviewed standalone financial results up to the end of the third quarter and audited annual standalone Ind AS financial statements respectively, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such standalone Ind AS financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as standalone financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



Independent Auditors' Report on quarterly standalone financial results and year to date standalone results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (Continued)

Astec LifeSciences Limited

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circulars dated 5 July 2016 and 10 August 2016 in this regard; and
- (ii) give a true and fair view of the standalone financial performance, including other comprehensive income and other financial information, for the quarter ended 31 March 2018 as well as the year to date results for the period from 1 April 2017 to 31 March 2018.

We draw attention to the fact that figures for the corresponding quarter ended 31 March 2017 and for the year ended 31 March 2017 included in the Statement are based on the previously issued standalone financial results that were audited by predecessor auditors vide their unmodified audit opinion dated 4 May 2017;

Our opinion is not modified in respect of the above matter.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022



Burjis Pardiwala
Partner
Membership No: 103595

Mumbai
2 May 2018



Sr. No	Particulars	CONSOLIDATED				
		3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue From Operations (Refer note 9)	12,836.09	7,428.50	9,050.25	37,084.52	31,340.35
II	Other Income	177.93	168.82	83.49	810.62	286.23
III	Total Income (I+II)	13,014.02	7,597.32	9,133.74	37,895.14	31,626.58
IV	Expenses					
	Cost of materials consumed	6,803.98	4,452.40	6,041.43	22,421.97	17,966.19
	Purchase of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,365.04	(111.17)	(430.18)	1,082.92	27.64
	Excise duty	-	-	436.74	326.10	1,472.89
	Employee benefits expense	548.19	558.62	642.16	2,170.82	2,037.57
	Finance costs	231.10	257.50	270.24	1,066.03	1,223.53
	Depreciation and amortisation expense	399.92	366.81	442.05	1,468.15	1,368.19
	Other expenses	999.41	1,188.77	715.58	4,203.20	3,596.06
	Total expenses (IV)	10,347.64	6,712.93	8,118.02	32,739.19	27,692.07
V	Profit / (loss) before exceptional items and tax (III - IV)	2,666.38	884.38	1,015.72	5,155.95	3,934.51
VI	Exceptional Items (Refer note 8)	-	415.21	(603.18)	415.21	(1,060.21)
VII	Profit / (loss) before tax (V+VI)	2,666.38	1,299.60	412.54	5,571.16	2,874.30
VIII	Tax Expense:					
	(1) Current tax	969.83	423.36	87.59	1,738.51	612.41
	(2) Deferred tax	(16.71)	34.81	(21.11)	207.77	344.03
	(3) Tax for previous years	(5.44)	126.58	-	121.14	-
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	1,718.70	714.85	346.06	3,503.74	1,917.86
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	1,718.70	714.85	346.06	3,503.74	1,917.86
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	16.62	(10.21)	(3.39)	(14.00)	(10.32)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(5.75)	3.53	1.18	4.85	3.58
	B (i) Items that will be reclassified to profit or loss	68.53	61.97	(0.29)	(29.88)	(0.29)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(23.85)	(21.50)	2.06	10.14	2.06
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	1,774.25	748.64	345.62	3,474.85	1,912.89
XVI	Net Profit/(loss) attributable to:					
	- Owners	1,715.70	716.07	346.05	3,490.40	1,911.77
	- Non controlling interests	3.00	(1.22)	0.01	13.34	6.09
	Total Comprehensive Income attributable to:					
	- Owners	1,771.25	749.86	345.61	3,461.51	1,906.80
	- Non controlling interests	3.00	(1.22)	0.01	13.34	6.09
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,952.77	1,952.77	1,951.29	1,952.77	1,951.29
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	15,012.25	11,850.89
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic	8.78	3.67	1.77	17.88	9.81
	(2) Diluted	8.77	3.66	1.77	17.84	9.78

Notes:


- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 2nd May, 2018.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2018 and 31st March, 2017 are the balancing figures between audited figures in respect of the full Financial Year and the published Year To Date figures upto the third Quarter of the Financial Year.
- The report of the Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results of the Company for the Quarter and Financial Year ended 31st March, 2018.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2018, subject to approval of the Shareholders at the ensuing 24th Annual General Meeting of the Company.
- Figures of corresponding previous year / period have been re-grouped/re-classified wherever necessary, to conform to this period's classification.
- Exceptional Items (as disclosed in the columns "3 months ended 31st December, 2017" and "Year ended 31st March, 2018" comprises (a) gain on mutually cancelled agreement for supply of product with one of its multi-national customer aggregating Rs. 1,932.83 Lakh; (b) inventory written off aggregating Rs. 727.83 Lakh; and (c) property, plant & equipment written off aggregating Rs. 789.79 Lakh. Exceptional Items (as disclosed in the columns "3 months ended 31st March 2017" and "Year ended 31st March, 2017" comprises property, plant & equipment written off aggregating to Rs. 603.18 Lakh and Rs. 1,060.21 Lakh respectively.
- According to the requirements of Ind-AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous Quarter ended 31st March, 2017 and for the Financial Year ended 31st March, 2017 were and are reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax (GST) from 1st July, 2017 replacing Excise duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the Quarters ended 31st March, 2018 and 31st December, 2017 is reported net of GST. Had the previously reported revenues were shown net of excise duty, comparative revenue of the Company would have been as follows:

(Rs. in Lakh)

Particulars	3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
Net revenue from operations	12,836.09	7,428.50	8,613.51	36,758.42	29,867.46

For Astec LifeSciences Limited

Ashok Hiremath
Managing Director
DIN :- 00349345
Wednesday, 2nd May, 2018, Mumbai



B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditors' Report on quarterly consolidated financial results and year to date consolidated results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To Board of Directors of Astec LifeSciences Limited

We have audited the accompanying consolidated financial results of Astec LifeSciences Limited ('the Holding Company') and its subsidiaries as listed in Annexure I, (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 31 March 2018 and the year to date results for the period from 1 April 2017 to 31 March 2018 ('the Statement'), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in these consolidated financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the current and previous financial year respectively. Also the figures up to the end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 2 May 2018.

These quarterly consolidated financial results as well as the year to date consolidated financial results have been prepared on the basis of the reviewed consolidated financial results up to the end of the third quarter and audited annual consolidated Ind AS financial statements respectively, which are the responsibility of the Holding Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such consolidated Ind AS financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as consolidated financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



Independent Auditors' Report on quarterly consolidated financial results and year to date consolidated results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (Continued)

Astec LifeSciences Limited

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us these quarterly consolidated financial results as well as the consolidated year to date results:

- (i) includes the financial results of three subsidiaries for the year ended 31 March 2018 (Refer Annexure I);
- (ii) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016 and 10 August 2016 in this regard; and
- (iii) give a true and fair view of the consolidated financial performance, including other comprehensive income and other financial information, for the quarter ended 31 March 2018 as well as the year to date results for the period from 1 April 2017 to 31 March 2018.

Other matters

- (i) We did not audit the financial statements of a subsidiary included in the consolidated quarterly financial results and consolidated year to date results, whose financial statements reflect total assets of Rs 90.32 lakhs and net assets of Rs 86.45 lakhs as at 31 March 2018, total revenues of Rs 10.80 lakhs and net cash inflows amounting to Rs 0.48 lakhs for the year ended on that date, as considered in the Consolidated Ind AS financial results. These financial statements have been audited by other auditor whose report has been furnished to us by the Management and our opinion on the Consolidated Ind AS financial results, in so far as it relates to the aforesaid subsidiary is based solely on the report of the other auditor.

We did not audit the financial statements of two subsidiaries whose financial statements reflect total assets of Rs 10.02 lakhs and net assets of Rs (12.85) lakhs as at 31 March 2018, total revenues of Rs. Nil and net cash outflows amounting to Rs 2.20 lakhs for the year ended on that date, as considered in the Consolidated Ind AS financial results. These financial statements of the aforesaid subsidiaries are unaudited and have been furnished to us by the Management of the Holding company and our opinion on the Consolidated Ind AS financial results, in so far as it relates to the aforesaid subsidiaries and associates is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management of the Holding company, these financial results are not material to the Group.

- (ii) The comparative consolidated financial results of the Holding Company for the quarter and for the year ended 31 March 2017, prepared in accordance with Ind AS, included in this Statement had been audited by the predecessor auditors who had expressed an unmodified opinion as per their reports dated 4 May 2017.

Our opinion is not modified in respect of these matters.

For **B S R & Co. LLP**
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Burjis Pardiwala
Partner

Membership No: 103595

Annexure I

List of entities consolidated as at 31 March 2018

Name of the Entity	Relationship
Behram Chemicals Private Limited	Subsidiary
Astec Europe Sprl	Subsidiary
Comercializadora Agricola Agroastrachem cia Ltda	Wholly Owned Subsidiary

CSB



Astec LifeSciences Limited
Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli(E), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Assets and Liabilities as at 31st March, 2018




(Rs. in Lakh)

PARTICULARS	STANDALONE		CONSOLIDATED	
	(Audited) 31st March, 2018	(Audited) 31st March, 2017	(Audited) 31st March, 2018	(Audited) 31st March, 2017
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	11,198.33	9,910.71	11,229.83	9,943.08
(b) Capital work-in-progress	4,178.29	755.53	4,178.26	755.53
(c) Investment property	-	-	-	-
(d) Goodwill	-	-	-	-
(e) Other Intangible assets	277.36	350.91	277.36	350.91
(f) Intangible assets under development	8.53	-	8.53	-
(g) Biological Assets other than bearer plants	-	-	-	-
(h) Investments in Subsidiaries	48.89	48.89	-	-
(i) Financial Assets				
(i) Investments	0.53	0.53	0.53	0.53
(ii) Trade receivables	-	-	-	-
(iii) Loans	194.93	133.69	205.05	143.81
(ii) Others	-	316.08	-	316.08
(j) Other Tax assets (net)	118.22	319.03	118.24	313.59
(k) Deferred tax assets (net)	-	-	-	-
(l) Other non-current assets	2,132.66	1,698.18	2,132.66	1,698.18
Total Non-current assets	18,157.74	13,533.55	18,150.46	13,521.71
(2) Current Assets				
(a) Inventories	7,847.83	6,555.14	7,847.83	6,555.14
(b) Financial Assets				
(i) Investments	-	-	-	-
(ii) Trade Receivables	12,313.41	11,065.08	12,314.80	11,066.26
(iii) Cash and cash equivalents	24.37	273.86	33.12	284.32
(iv) Bank balances other than (iii) above	116.63	138.79	116.63	138.79
(v) Loans	2.32	8.06	2.32	8.06
(vi) Others	82.17	56.08	82.17	56.08
(c) Other current assets	2,769.38	1,728.38	2,771.04	1,728.65
Total Current Assets	23,156.11	19,825.39	23,167.91	19,837.30
Total Assets	41,313.85	33,358.94	41,318.37	33,359.01
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,952.77	1,951.29	1,952.77	1,951.29
(b) Other Equity	15,015.92	11,847.26	15,012.25	11,850.89
(c) Non controlling interest	-	-	28.39	15.04
Total Equity	16,968.69	13,798.55	16,993.41	13,817.22
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	24.88	40.19	24.88	40.19
(ii) Trade payables	-	-	-	-
(iii) Other financial liabilities	-	-	-	-
(b) Provisions	16.52	6.64	16.52	6.64
(c) Deferred tax liabilities (Net)	443.85	119.55	444.78	122.67
(d) Other non-current liabilities	-	-	-	-
Total Non Current Liabilities	485.25	166.38	486.18	169.50
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	12,417.28	12,599.88	12,417.28	12,599.88
(ii) Trade payables	10,023.75	5,737.36	9,993.00	5,707.06
(iii) Other financial liabilities	1,328.08	694.51	1,330.13	696.49
(b) Other current liabilities	46.77	306.57	54.34	313.17
(c) Provisions	44.03	55.69	44.03	55.69
(d) Current Tax Liabilities (Net)	-	-	-	-
Total Current Liabilities	23,859.91	19,394.01	23,838.78	19,372.29
Total Equity and Liabilities	41,313.85	33,358.94	41,318.37	33,359.01

For Astec LifeSciences Limited

Ashok Hiremath
Managing Director
DIN:- 00349345
Wednesday, 2nd May, 2018, Mumbai



MACHINE READABLE AND
SEARCHABLE FOMAT



Astec LifeSciences Limited
Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli(East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Standalone Financial Results for the Quarter and Financial Year ended 31st March, 2018



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	STANDALONE				
		3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue From Operations (Refer note 9)	12,836.09	7,428.50	9,045.73	37,084.52	31,275.74
II	Other Income	177.93	168.82	83.40	810.62	284.54
III	Total Income (I+II)	13,014.02	7,597.32	9,129.13	37,895.14	31,560.28
IV	Expenses					
	Cost of materials consumed	6,803.98	4,452.40	6,037.64	22,421.97	17,912.07
	Purchase of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,365.04	(111.17)	(430.18)	1,082.92	27.64
	Excise duty	-	-	436.74	326.10	1,472.89
	Employee benefits expense	548.19	558.62	642.16	2,170.82	2,037.57
	Finance costs	231.02	257.46	270.12	1,065.90	1,222.98
	Depreciation and amortisation expense	399.70	366.59	441.83	1,467.27	1,367.31
	Other expenses	1,005.15	1,184.35	712.59	4,207.59	3,596.89
	Total expenses (IV)	10,353.08	6,708.25	8,110.90	32,742.57	27,637.35
V	Profit / (loss) before exceptional items and tax (III - IV)	2,660.94	889.07	1,018.23	5,152.57	3,922.93
VI	Exceptional Items (Refer note 8)	-	415.21	(603.18)	415.21	(1,060.21)
VII	Profit / (loss) before tax (V+VI)	2,660.94	1,304.28	415.05	5,567.78	2,862.72
VIII	Tax Expense:					
	(1) Current tax	968.57	424.15	86.94	1,737.13	609.27
	(2) Deferred tax	(17.42)	35.31	(21.11)	206.99	344.03
	(3) Tax for earlier years	-	126.58	-	126.58	-
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	1,709.79	718.24	349.22	3,497.08	1,909.42
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	1,709.79	718.24	349.22	3,497.08	1,909.42
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	16.62	(10.21)	(3.39)	(14.00)	(10.32)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(5.75)	3.53	1.18	4.85	3.58
	B (i) Items that will be reclassified to profit or loss	68.92	62.14	(5.96)	(29.29)	(5.96)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(23.85)	(21.50)	2.06	10.14	2.06
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period)	1,765.73	752.20	343.11	3,468.78	1,898.78
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,952.77	1,952.77	1,951.29	1,952.77	1,951.29
XVII	Other Equity excluding Revaluation Reserve	-	-	-	15,015.92	11,847.26
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic	8.76	3.68	1.79	17.91	9.79
	(2) Diluted	8.74	3.67	1.79	17.88	9.77

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 2nd May, 2018.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2018 and 31st March, 2017 are the balancing figures between audited figures in respect of the full Financial Year and the published Year To Date figures upto the third Quarter of the Financial Year.
- The report of the Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results of the Company for the Quarter and Financial Year ended 31st March, 2018.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2018, subject to approval of the Shareholders at the ensuing 24th Annual General Meeting of the Company.
- Figures of corresponding previous year / period have been re-grouped/re-classified wherever necessary, to conform to this period's classification.
- Exceptional Items (as disclosed in the columns "3 months ended 31st December, 2017" and "Year ended 31st March, 2018" comprises (a) gain on mutually cancelled agreement for supply of product with one of its multi-national customer aggregating Rs. 1,932.83 Lakh; (b) inventory written off aggregating Rs. 727.83 Lakh; and (c) property, plant & equipment written off aggregating Rs. 789.79 Lakh.
Exceptional Items (as disclosed in the columns "3 months ended 31st March 2017" and "Year ended 31st March, 2017" comprises property, plant & equipment written off aggregating to Rs. 603.18 Lakh and Rs. 1,060.21 Lakh respectively.
- According to the requirements of Ind-AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous Quarter ended 31st March, 2017 and for the Financial Year ended 31st March, 2017 were and are reported inclusive of Excise Duty.
The Government of India has implemented Goods and Service Tax (GST) from 1st July, 2017 replacing Excise duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the Quarters ended 31st March, 2018 and 31st December, 2017 is reported net of GST. Had the previously reported revenues were shown net of excise duty, comparative revenue of the Company would have been as follows:

(Rs. in Lakh)

Particulars	3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
Net revenue from operations	12,836.09	7,428.50	8,608.99	36,758.42	29,802.85

For Astec LifeSciences Limited

Sd/-
Ashok Hiremath
Managing Director
DIN :- 00349345
Wednesday, 2nd May, 2018, Mumbai

Independent Auditors' Report on quarterly standalone financial results and year to date standalone results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To Board of Directors of
Astec LifeSciences Limited

We have audited the accompanying standalone financial results of Astec LifeSciences Limited ('the Company') for the quarter ended 31 March 2018 and the year to date results for the period from 1 April 2017 to 31 March 2018 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in these standalone financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the current and previous financial year respectively. Also, the figures up to the end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 2 May 2018.

These quarterly standalone financial results as well as the year to date standalone financial results have been prepared on the basis of the reviewed standalone financial results up to the end of the third quarter and audited annual standalone Ind AS financial statements respectively, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such standalone Ind AS financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as standalone financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Independent Auditors' Report on quarterly standalone financial results and year to date standalone results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (Continued)

Astec LifeSciences Limited

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circulars dated 5 July 2016 and 10 August 2016 in this regard; and
- (ii) give a true and fair view of the standalone financial performance, including other comprehensive income and other financial information, for the quarter ended 31 March 2018 as well as the year to date results for the period from 1 April 2017 to 31 March 2018.

We draw attention to the fact that figures for the corresponding quarter ended 31 March 2017 and for the year ended 31 March 2017 included in the Statement are based on the previously issued standalone financial results that were audited by predecessor auditors vide their unmodified audit opinion dated 4 May 2017;

Our opinion is not modified in respect of the above matter.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Mumbai
2 May 2018

Sd/-
Burjis Pardiwala
Partner
Membership No: 103595



Rs. in Lakh (Except per Equity Share data)

Sr. No	Particulars	CONSOLIDATED				
		3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue From Operations (Refer note 9)	12,836.09	7,428.50	9,050.25	37,084.52	31,340.35
II	Other Income	177.93	168.82	83.49	810.62	286.23
III	Total Income (I+II)	13,014.02	7,597.32	9,133.74	37,895.14	31,626.58
IV	Expenses					
	Cost of materials consumed	6,803.98	4,452.40	6,041.43	22,421.97	17,966.19
	Purchase of Stock-in-Trade	-	-	-	-	-
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,365.04	(111.17)	(430.18)	1,082.92	27.64
	Excise duty	-	-	436.74	326.10	1,472.89
	Employee benefits expense	548.19	558.62	642.16	2,170.82	2,037.57
	Finance costs	231.10	257.50	270.24	1,066.03	1,223.53
	Depreciation and amortisation expense	399.92	366.81	442.05	1,468.15	1,368.19
	Other expenses	999.41	1,188.77	715.58	4,203.20	3,596.06
	Total expenses (IV)	10,347.64	6,712.93	8,118.02	32,739.19	27,692.07
V	Profit / (loss) before exceptional items and tax (III - IV)	2,666.38	884.38	1,015.72	5,155.95	3,934.51
VI	Exceptional Items (Refer note 8)	-	415.21	(603.18)	415.21	(1,060.21)
VII	Profit / (loss) before tax (V+VI)	2,666.38	1,299.60	412.54	5,571.16	2,874.30
VIII	Tax Expense:					
	(1) Current tax	969.83	423.36	87.59	1,738.51	612.41
	(2) Deferred tax	(16.71)	34.81	(21.11)	207.77	344.03
	(3) Tax for previous years	(5.44)	126.58	-	121.14	-
IX	Profit / (loss) for the period from continuing operations (VII-VIII)	1,718.70	714.85	346.06	3,503.74	1,917.86
X	Profit / (loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit / (loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit / (loss) for the period (IX + XII)	1,718.70	714.85	346.06	3,503.74	1,917.86
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	16.62	(10.21)	(3.39)	(14.00)	(10.32)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(5.75)	3.53	1.18	4.85	3.58
	B (i) Items that will be reclassified to profit or loss	68.53	61.97	(0.29)	(29.88)	(0.29)
	(ii) Income tax relating to items that will be reclassified to profit or loss	(23.85)	(21.50)	2.06	10.14	2.06
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	1,774.25	748.64	345.62	3,474.85	1,912.89
XVI	Net Profit/(loss) attributable to:					
	- Owners	1,715.70	716.07	346.05	3,490.40	1,911.77
	- Non controlling interests	3.00	(1.22)	0.01	13.34	6.09
	Total Comprehensive Income attributable to:					
	- Owners	1,771.25	749.86	345.61	3,461.51	1,906.80
	- Non controlling interests	3.00	(1.22)	0.01	13.34	6.09
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,952.77	1,952.77	1,951.29	1,952.77	1,951.29
XVIII	Other Equity excluding Revaluation Reserve	-	-	-	15,012.25	11,850.89
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinued operations) (non-annualised) :					
	(1) Basic	8.78	3.67	1.77	17.88	9.81
	(2) Diluted	8.77	3.66	1.77	17.84	9.78

Notes:

- The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Wednesday, 2nd May, 2018.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind-AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.
- The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The figures for the Quarter ended 31st March, 2018 and 31st March, 2017 are the balancing figures between audited figures in respect of the full Financial Year and the published Year To Date figures upto the third Quarter of the Financial Year.
- The report of the Statutory Auditors is with unmodified opinion with respect to the Audited Financial Results of the Company for the Quarter and Financial Year ended 31st March, 2018.
- The Board of Directors have recommended Final Dividend of 15% of Equity Share Capital of the Company, i.e. Rs. 1.50 per Equity Share of Face Value of Rs. 10/- each for the Financial Year ended 31st March, 2018, subject to approval of the Shareholders at the ensuing 24th Annual General Meeting of the Company.
- Figures of corresponding previous year / period have been re-grouped/re-classified wherever necessary, to conform to this period's classification.
- Exceptional Items (as disclosed in the columns "3 months ended 31st December, 2017" and "Year ended 31st March, 2018" comprises (a) gain on mutually cancelled agreement for supply of product with one of its multi-national customer aggregating Rs. 1,932.83 Lakh; (b) inventory written off aggregating Rs. 727.83 Lakh; and (c) property, plant & equipment written off aggregating Rs. 789.79 Lakh.
Exceptional Items (as disclosed in the columns "3 months ended 31st March 2017" and "Year ended 31st March, 2017" comprises property, plant & equipment written off aggregating to Rs. 603.18 Lakh and Rs. 1,060.21 Lakh respectively.
- According to the requirements of Ind-AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, revenue for the corresponding previous Quarter ended 31st March, 2017 and for the Financial Year ended 31st March, 2017 were and are reported inclusive of Excise Duty.
The Government of India has implemented Goods and Service Tax (GST) from 1st July, 2017 replacing Excise duty, Service Tax and various other indirect taxes. As per Ind AS 18, the revenue for the Quarters ended 31st March, 2018 and 31st December, 2017 is reported net of GST. Had the previously reported revenues were shown net of excise duty, comparative revenue of the Company would have been as follows:

(Rs. in Lakh)

Particulars	3 months ended 31st March, 2018	3 months ended 31st December, 2017	3 months ended 31st March, 2017	Year ended 31st March, 2018	Year ended 31st March, 2017
Net revenue from operations	12,836.09	7,428.50	8,613.51	36,758.42	29,867.46

For Astec LifeSciences Limited

Sd/-

Ashok Hiremath
Managing Director
DIN : 00349345
Wednesday, 2nd May, 2018, Mumbai

Independent Auditors' Report on quarterly consolidated financial results and year to date consolidated results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

**To Board of Directors of
Astec LifeSciences Limited**

We have audited the accompanying consolidated financial results of Astec LifeSciences Limited ('the Holding Company') and its subsidiaries as listed in Annexure I, (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 31 March 2018 and the year to date results for the period from 1 April 2017 to 31 March 2018 ('the Statement'), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended 31 March 2018 and the corresponding quarter ended in the previous year as reported in these consolidated financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the current and previous financial year respectively. Also the figures up to the end of the third quarter for the current and previous financial year had only been reviewed and not subjected to audit. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors in their meeting held on 2 May 2018.

These quarterly consolidated financial results as well as the year to date consolidated financial results have been prepared on the basis of the reviewed consolidated financial results up to the end of the third quarter and audited annual consolidated Ind AS financial statements respectively, which are the responsibility of the Holding Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such consolidated Ind AS financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as consolidated financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Independent Auditors' Report on quarterly consolidated financial results and year to date consolidated results of Astec LifeSciences Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (Continued)

Astec LifeSciences Limited

Based on our audit conducted as above, in our opinion and to the best of our information and according to the explanations given to us these quarterly consolidated financial results as well as the consolidated year to date results:

- (i) includes the financial results of three subsidiaries for the year ended 31 March 2018 (Refer Annexure D);
- (ii) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5 July 2016 and 10 August 2016 in this regard; and
- (iii) give a true and fair view of the consolidated financial performance, including other comprehensive income and other financial information, for the quarter ended 31 March 2018 as well as the year to date results for the period from 1 April 2017 to 31 March 2018.

Other matters

- (i) We did not audit the financial statements of a subsidiary included in the consolidated quarterly financial results and consolidated year to date results, whose financial statements reflect total assets of Rs 90.32 lakhs and net assets of Rs 86.45 lakhs as at 31 March 2018, total revenues of Rs 10.80 lakhs and net cash inflows amounting to Rs 0.48 lakhs for the year ended on that date, as considered in the Consolidated Ind AS financial results. These financial statements have been audited by other auditor whose report has been furnished to us by the Management and our opinion on the Consolidated Ind AS financial results, in so far as it relates to the aforesaid subsidiary is based solely on the report of the other auditor.

We did not audit the financial statements of two subsidiaries whose financial statements reflect total assets of Rs 10.02 lakhs and net assets of Rs (12.85) lakhs as at 31 March 2018, total revenues of Rs. Nil and net cash outflows amounting to Rs 2.20 lakhs for the year ended on that date, as considered in the Consolidated Ind AS financial results. These financial statements of the aforesaid subsidiaries are unaudited and have been furnished to us by the Management of the Holding company and our opinion on the Consolidated Ind AS financial results, in so far as it relates to the aforesaid subsidiaries and associates is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management of the Holding company, these financial results are not material to the Group.

- (ii) The comparative consolidated financial results of the Holding Company for the quarter and for the year ended 31 March 2017, prepared in accordance with Ind AS, included in this Statement had been audited by the predecessor auditors who had expressed an unmodified opinion as per their reports dated 4 May 2017.

Our opinion is not modified in respect of these matters.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Sd/-
Burjis Pardiwala
Partner
Membership No: 103595

Mumbai
2 May 2018

Annexure I

List of entities consolidated as at 31 March 2018

Name of the Entity	Relationship
Behram Chemicals Private Limited	Subsidiary
Astec Europe Spri	Subsidiary
Comercializadora Agricola Agroastrachem cia Ltda	Wholly Owned Subsidiary



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli(E), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.:022-25195768, Fax no.: 022-22618289, Email id: astecinfo@godrejastec.com

Statement of Assets and Liabilities as at 31st March, 2018



Responsible Care®

FOR COMMITMENT TO EXCELLENCE

PARTICULARS	STANDALONE		CONSOLIDATED	
	(Audited)	(Audited)	(Audited)	(Audited)
	31st March, 2018	31st March, 2017	31st March, 2018	31st March, 2017
(Rs. in Lakh)				
ASSETS				
(1) Non-current assets				
(a) Property, Plant and Equipment	11,198.33	9,910.71	11,229.83	9,943.08
(b) Capital work-in-progress	4,178.29	755.53	4,178.26	755.53
(c) Investment property	-	-	-	-
(d) Goodwill	-	-	-	-
(e) Other Intangible assets	277.36	350.91	277.36	350.91
(f) Intangible assets under development	8.53	-	8.53	-
(g) Biological Assets other than bearer plants	-	-	-	-
(h) Investments in Subsidiaries	48.89	48.89	-	-
(i) Financial Assets				
(i) Investments	0.53	0.53	0.53	0.53
(ii) Trade receivables	-	-	-	-
(iii) Loans	194.93	133.69	205.05	143.81
(ii) Others	-	316.08	-	316.08
(j) Other Tax assets (net)	118.22	319.03	118.24	313.59
(k) Deferred tax assets (net)	-	-	-	-
(l) Other non-current assets	2,132.66	1,698.18	2,132.66	1,698.18
Total Non-current assets	18,157.74	13,533.55	18,150.46	13,521.71
(2) Current Assets				
(a) Inventories	7,847.83	6,555.14	7,847.83	6,555.14
(b) Financial Assets				
(i) Investments	-	-	-	-
(ii) Trade Receivables	12,313.41	11,065.08	12,314.80	11,066.26
(iii) Cash and cash equivalents	24.37	273.86	33.12	284.32
(iv) Bank balances other than (iii) above	116.63	138.79	116.63	138.79
(v) Loans	2.32	8.06	2.32	8.06
(vi) Others	82.17	56.08	82.17	56.08
(c) Other current assets	2,769.38	1,728.38	2,771.04	1,728.65
Total Current Assets	23,156.11	19,825.39	23,167.91	19,837.30
Total Assets	41,313.85	33,358.94	41,318.37	33,359.01
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,952.77	1,951.29	1,952.77	1,951.29
(b) Other Equity	15,015.92	11,847.26	15,012.25	11,850.89
(c) Non controlling interest	-	-	28.39	15.04
Total Equity	16,968.69	13,798.55	16,993.41	13,817.22
LIABILITIES				
(1) Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	24.88	40.19	24.88	40.19
(ii) Trade payables	-	-	-	-
(iii) Other financial liabilities	-	-	-	-
(b) Provisions	16.52	6.64	16.52	6.64
(c) Deferred tax liabilities (Net)	443.85	119.55	444.78	122.67
(d) Other non-current liabilities	-	-	-	-
Total Non Current Liabilities	485.25	166.38	486.18	169.50
(2) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	12,417.28	12,599.88	12,417.28	12,599.88
(ii) Trade payables	10,023.75	5,737.36	9,993.00	5,707.06
(iii) Other financial liabilities	1,328.08	694.51	1,330.13	696.49
(b) Other current liabilities	46.77	306.57	54.34	313.17
(c) Provisions	44.03	55.69	44.03	55.69
(d) Current Tax Liabilities (Net)	-	-	-	-
Total Current Liabilities	23,859.91	19,394.01	23,838.78	19,372.29
Total Equity and Liabilities	41,313.85	33,358.94	41,318.37	33,359.01

For Astec LifeSciences Limited

Sd/-

Ashok Hiremath

Managing Director

DIN :- 00349345

Wednesday, 2nd May, 2018, Mumbai